Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
Alector, Inc. (ALEC)
Last alector, inc. earnings: 3/24 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)-- --Latozinemab, a novel investigational human monoclonal antibody, is the most advanced PGRN-elevating candidate in development for the treatment of FTD-GRN-- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the presentation of a poster on participant baseline characteristics for the pivotal INFRONT-3 Phase 3 clinical trial evaluating the safety and efficacy of latozinemab in potentially slowing disease progression in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). The conference is being held in Amsterdam from September 19 – 22, 2024. Heterozygous loss-of-function mutations in the GRN gene cause FTD du
Show less
Read more
Impact Snapshot
Event Time:
ALEC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALEC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALEC alerts
High impacting Alector, Inc. news events
Weekly update
A roundup of the hottest topics
ALEC
News
- Alector, Inc. (NASDAQ: ALEC) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $2.50 price target on the stock, down previously from $9.00.MarketBeat
- Alector, Inc. (NASDAQ: ALEC) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $4.00 price target on the stock.MarketBeat
- Alector, Inc. (NASDAQ: ALEC) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating. They now have a $1.00 price target on the stock, down previously from $9.00.MarketBeat
- Alector, Inc. (NASDAQ: ALEC) had its price target lowered by analysts at HC Wainwright from $35.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study [Yahoo! Finance]Yahoo! Finance
ALEC
Earnings
- 11/6/24 - Beat
ALEC
Sec Filings
- 12/6/24 - Form SC
- 12/3/24 - Form 4
- 12/3/24 - Form 4
- ALEC's page on the SEC website